ArticleWorld journal of urology2018

PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study.

Peter Hammerer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.